GAL and melanoma: When the α-Gal glycolipids were administered to primary melanoma lesions in anti-Gal producing α-1,3-galactosyltransferase knockout (α1,3GT−/−) mice, i.e., mice lacking α-Gal epitopes, the mice were protected from the development of secondary untreated lesions [15, 16].